Last reviewed · How we verify

AM-101 — Competitive Intelligence Brief

AM-101 (AM-101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Otolaryngology / Neurology.

phase 3 NMDA receptor antagonist NMDA receptor Otolaryngology / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AM-101 (AM-101) — Auris Medical AG. AM-101 is an intratympanic injection that delivers a small-molecule NMDA receptor antagonist to the inner ear to reduce tinnitus perception.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AM-101 TARGET AM-101 Auris Medical AG phase 3 NMDA receptor antagonist NMDA receptor
Namenda MEMANTINE AbbVie marketed N-methyl-D-aspartate Receptor Antagonist Glutamate NMDA receptor; GRIN1/GRIN2A 2003-01-01
Felbatol FELBAMATE Mylan Speciality Lp marketed Anti-epileptic Agent [EPC] NMDA receptor-ionophore complex 1993-01-01
QUINIDINE QUINIDINE marketed sigma-1 receptor, NMDA receptor, CYP2D6 1950-01-01
Methadone Hydrochloride METHADONE Specgx Llc marketed Opioid Agonist mu-opioid receptors, NMDA receptor 1947-01-01
Ketamine load Ketamine load University of Pennsylvania marketed NMDA receptor antagonist NMDA receptor
Intra-nasal ketamine Intra-nasal ketamine Lions Gate Hospital marketed NMDA receptor antagonist NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

  1. Turku University Hospital · 3 drugs in this class
  2. H. Lundbeck A/S · 2 drugs in this class
  3. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
  4. Shalvata Mental Health Center · 2 drugs in this class
  5. New York State Psychiatric Institute · 2 drugs in this class
  6. Auris Medical AG · 1 drug in this class
  7. AstraZeneca · 1 drug in this class
  8. Alameda Health System · 1 drug in this class
  9. Centre Hospitalier Universitaire de Nice · 1 drug in this class
  10. Asker & Baerum Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AM-101 — Competitive Intelligence Brief. https://druglandscape.com/ci/am-101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: